A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets

A Taguchi, AD Taylor, J Rodriguez, M Çeliktaş, H Liu… - Cancer research, 2014 - AACR
A Taguchi, AD Taylor, J Rodriguez, M Çeliktaş, H Liu, X Ma, Q Zhang, CH Wong, A Chin…
Cancer research, 2014AACR
Cancer/testis (CT) antigens are potential immunotherapeutic targets in cancer. However, the
expression of particular antigens is limited to a subset of tumors of a given type. Thus, there
is a need to identify antigens with complementary expression patterns for effective
therapeutic intervention. In this study, we searched for genes that were distinctly expressed
at a higher level in lung tumor tissue and the testes compared with other nontumor tissues
and identified members of the VCX/Y gene family as novel CT antigens. VCX3A, a member …
Abstract
Cancer/testis (CT) antigens are potential immunotherapeutic targets in cancer. However, the expression of particular antigens is limited to a subset of tumors of a given type. Thus, there is a need to identify antigens with complementary expression patterns for effective therapeutic intervention. In this study, we searched for genes that were distinctly expressed at a higher level in lung tumor tissue and the testes compared with other nontumor tissues and identified members of the VCX/Y gene family as novel CT antigens. VCX3A, a member of the VCX/Y gene family, was expressed at the protein level in approximately 20% of lung adenocarcinomas and 35% of squamous cell carcinomas, but not expressed in normal lung tissues. Among CT antigens with concordant mRNA and protein expression levels, four CT antigens, XAGE1, VCX, IL13RA2, and SYCE1, were expressed, alone or in combination, in about 80% of lung adenocarcinoma tumors. The CT antigen VCX/Y gene family broadens the spectrum of CT antigens expressed in lung adenocarcinomas for clinical applications. Cancer Res; 74(17); 4694–705. ©2014 AACR.
AACR